<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0375-0760</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina Tropical]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Med Trop]]></abbrev-journal-title>
<issn>0375-0760</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0375-07602005000100020</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Evaluation of two different potency tests for leptospirosis vaccine vax-SPIRAL®]]></article-title>
<article-title xml:lang="es"><![CDATA[Evaluación de 2 pruebas diferentes de potencia para la vacuna vax-SPIRALâ contra la leptospirosis]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Núñez]]></surname>
<given-names><![CDATA[. Juan Francisco]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fajardo]]></surname>
<given-names><![CDATA[Ester María]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[Elizabeth]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ontivero]]></surname>
<given-names><![CDATA[Ivis]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[Deolinda]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Instituto Finlay  ]]></institution>
<addr-line><![CDATA[Ciudad de La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2005</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2005</year>
</pub-date>
<volume>57</volume>
<numero>1</numero>
<fpage>67</fpage>
<lpage>68</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0375-07602005000100020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0375-07602005000100020&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0375-07602005000100020&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Two different potency tests were evaluated, consisting in one-dilution used to determine 50 % lethal dose (LD50) and four-dilution used to calculate 50 % effective dose (ED50), respectively. Our experience has led to propose the four-dilution test for routine lot releasing.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Se evaluaron 2 pruebas diferentes de potencia, consistentes en una dilución usada para determinar 50 % de dosis letal (DL50) y 4 diluciones utilizadas para calcular 50 % de dosis efectiva (DE50), respectivamente. La experiencia de los autores de este trabajo los conduce a proponer la prueba con dilución 4 para la liberación de rutina del lote.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Vax-SPIRAL]]></kwd>
<kwd lng="en"><![CDATA[leptospirosis]]></kwd>
<kwd lng="en"><![CDATA[potency test]]></kwd>
<kwd lng="es"><![CDATA[Vax-SPIRAL]]></kwd>
<kwd lng="es"><![CDATA[leptospirosis]]></kwd>
<kwd lng="es"><![CDATA[prueba de potencia]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <div class=Section1>         <p class=MsoNormal><span style='mso-bookmark:nunez1'>Instituto <span class=SpellE>Finlay</span></span></p>   <h2 class=MsoNormal><span style='mso-bookmark:nunez1'><span class=SpellE>Evaluation</span>      <span class=SpellE>of</span> <span class=SpellE>two</span> <span class=SpellE>different</span>      <span class=SpellE>potency</span> <span class=SpellE>tests</span> <span class=SpellE>for</span> <span class=SpellE>leptospirosis</span> <span class=SpellE>vaccine</span> <span class=SpellE>vax</span>-SPIRAL</span><span style='mso-bookmark:nunez1'><sup><span lang=EN-US style='mso-ansi-language: EN-US'>®</span></sup></span></h2>       <p class=MsoNormal><span style='mso-bookmark:nunez1'><a href="#creditos">Dr.      Juan Francisco Núñez<span class=GramE>,<sup>1</sup></span> Lic. Ester María Fajardo<span class=GramE>,<sup>2</sup></span>      Lic. Elizabeth Pérez<span class=GramE>,<sup>3</sup></span> Lic. <span class=SpellE>Ivis</span> <span class=SpellE>Ontivero</span><span class=GramE>,<sup>3</sup></span>      Dra. <span class=SpellE>Deolinda</span> Silva<sup>3</sup> y Dr. Pedro Muñoz<sup>4</sup></a><sup><a name="autores"></a></sup></span></p>   <h4 class=MsoNormal><span style='mso-bookmark:nunez1'><span lang=EN-US style='mso-ansi-language:EN-US'>Summary</span></span></h4>       <p class=MsoNormal><span style='mso-bookmark:nunez1'><span lang=EN-US style='mso-ansi-language:EN-US'>Two different potency tests were evaluated, consisting      in one-dilution used to determine 50 % lethal dose (LD<sub>50</sub>) and four-dilution      used to calculate 50 % effective dose (ED<sub>50</sub>), respectively. Our      experience has led to propose the four-dilution test for routine lot releasing.</span></span></p>       <p class=MsoNormal><span style='mso-bookmark:nunez1'><span class=SpellE><b>Key</b></span>      <b><span class=SpellE>words</span></b>: <span class=SpellE>Vax</span>-SPIRAL,      <span class=SpellE>leptospirosis</span>, <span class=SpellE>potency</span> <span class=SpellE>test</span>.</span></p>       <p><span style='mso-bookmark:nunez1'></span> </p>       <p><span lang=EN-US style='mso-ansi-language:EN-US'>Potency test for the trivalent      leptospirosis vaccine vax-SPIRAL<sup>®1</sup> is based on the protection of      hamsters against lethal challenge with virulent organisms. Two tests were      developed, consisting in one-dilution and four- dilution respectively. The      former is used as a routine lot-release test and the latter for stability      studies.</span> </p>       <p class=MsoNormal><span lang=EN-US style='mso-ansi-language:EN-US'>In the one-<b>      </b>dilution test, 42 hamsters (<span class=SpellE><i>Mesocricetus</i></span><i>      <span class=SpellE>auratus</span></i>), 40-60 g, are separated for each <span class=SpellE>serovar</span> contained in the vaccine (<span class=SpellE><i>canicola</i></span><i>      <span class=SpellE>canicola</span>; <span class=SpellE>icterohaemorrhagiae</span>      <span class=SpellE>copenhageni</span>; </i></span><st1:City><st1:place><span   class=SpellE><span class=GramE><i><span lang=EN-US style='mso-ansi-language:   EN-US'>pomona</span></i></span></span></st1:place></st1:City><i><span lang=EN-US style='mso-ansi-language:EN-US'> <span class=SpellE>mozdok</span></span></i><span lang=EN-US style='mso-ansi-language:EN-US'>); 6 receive intramuscularly 0.5 <span class=SpellE>mL</span> of the vaccine, diluted 1:5. Other 36 hamsters (controls)      are used to determine 50 % Lethal Dose (LD<sub>50</sub>) and challenge dose      (total: 126 hamsters). Challenge is done two weeks later, with 0.5 <span class=SpellE>mL</span>      of virulent leptospiras, <span class=SpellE>intraperitoneally</span>. Then,      the animals are observed for another two weeks. The lot passes the test if      80 % of the immunized animals survive, and 80 % of controls receiving the      challenge dose die.<sup>2</sup></span></p>       <p class=MsoNormal><span lang=EN-US style='mso-ansi-language:EN-US'>The four-dilution      test differs only from the former in the fact that 60 hamsters are required      per each <span class=SpellE>serovar</span>; groups of 6 animals are immunized      with fivefold <span class=GramE>dilutions</span> (1:5-1:625) respectively.      </span></p>       <p class=MsoNormal><span lang=EN-US style='mso-ansi-language:EN-US'>Although      the requirement for potency is the same, this test permits to calculate 50      % Effective Dose (ED<sub>50</sub>), allowing the discrimination between the      protective capacity of lots in a quantitative form. Our eight-year experience      has led to propose the four-<b> </b>dilution test for routine lot releasing,      although its expensiveness, as potency can be expressed in much more confident      terms, enabling the use of Control Graphs to meet the requirements of our      National Control Authority.</span></p>   <h4 class=MsoNormal><span class=SpellE><span style='mso-fareast-language:ES-MX'>Acknowledgement</span></span></h4>       ]]></body>
<body><![CDATA[<p class=MsoNormal><span lang=EN-US style='mso-ansi-language:EN-US'>To doctors      Eduardo Alvarez and <span class=SpellE>Adelina</span> <span class=SpellE>Chávez</span>,      to <span class=SpellE>bachellor</span> Bernardo Ortiz and to the technicians      Eduardo <span class=SpellE>Cajuso</span>, Boris Ruiz, <span class=SpellE>Regla</span>      Sosa and Irma Labrador for their participation in this paper.</span></p>       <p class=MsoNormal>&nbsp;</p>   <h2 class=MsoNormal>Evaluación de 2 pruebas diferentes de potencia para la vacuna      <span class=SpellE>vax</span>-SPIRAL<span lang=EN-US style='font-family:Symbol; mso-ascii-font-family:Arial;mso-hansi-font-family:Arial;mso-ansi-language:EN-US; mso-char-type:symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type: symbol;mso-symbol-font-family:Symbol'>â</span></span> contra la <span class=SpellE>leptospirosis</span> </h2>   <h4 class=MsoNormal>Resumen</h4>       <p class=MsoNormal>Se evaluaron 2 pruebas diferentes de potencia, consistentes      en una dilución usada para determinar 50 % de dosis letal (DL<sub>50</sub>)      y 4 diluciones utilizadas para calcular 50 % de dosis efectiva (DE<sub>50</sub>),      respectivamente. La experiencia de los autores de este trabajo los conduce      a proponer la prueba con dilución 4 para la liberación de rutina del lote.</p>       <p class=MsoNormal><b>Palabras clave</b>: <span class=SpellE>Vax</span>-SPIRAL,      <span class=SpellE>leptospirosis</span>, prueba de potencia.</p>       <!-- ref --><p class=MsoNormal>&nbsp;<!-- ref -->Fajardo EM. Normalización        de la dosis letal 50 % de cepas de <i>Leptospira <span      class=SpellE>interrogans</span> </i>utilizadas en el control de la vacuna        antileptospirósica cubana para uso humano. <span class=SpellE>Rev</span>        Cubana <span class=SpellE>Med</span> <span class=SpellE>Trop</span> 1998<span      class=GramE>;50</span>(1):22-6.<i></i></li>    </ol>       <p class=MsoNormal>Recibido: 27 de diciembre de 2004. Aprobado; 10 de marzo      de 2005.    <br>     Dr. <i style='mso-bidi-font-style:normal'>Juan Francisco Núñez.</i> Instituto      <span class=SpellE>Finlay</span>. Ave. 27 No. 19805, municipio La Lisa, Ciudad      de La Habana. Cuba, CP 11600. Correo electrónico: <span style='color:windowtext;text-decoration: none;text-underline:none'><a href="mailto:%20jnunez@finlay.edu.cu">jnunez@finlay.edu.cu</a></span>    </p>       <p class=MsoNormal><sup><a href="#autores">1 </a></sup><a href="#autores">Médico      Veterinario. Investigador Agregado. Profesor Adjunto.    ]]></body>
<body><![CDATA[<br>     <sup>2 </sup><span class=SpellE>Máster</span> en Ciencias Bioquímicas. Licenciada      en Biología. Investigadora Auxiliar.    <br>     <sup>3 </sup>Licenciada en Ciencias Farmacéuticas.    <br>     <sup>4 </sup>Médico Veterinario.</a><a name="creditos"></a></p>  </div>      ]]></body><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[vax-SPIRAL® Vacuna antileptospirósica trivalente para el uso humano; investigación, desarrollo e impacto sobre la enfermedad en Cuba]]></article-title>
<source><![CDATA[Biotecnología Aplicada]]></source>
<year>2004</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>107-11</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fajardo]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Normalización de la dosis letal 50 % de cepas de Leptospira interrogans utilizadas en el control de la vacuna antileptospirósica cubana para uso humano]]></article-title>
<source><![CDATA[Rev Cubana Med Trop]]></source>
<year>1998</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
